HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US COVID-19 Fraud: FTC Points To Peptides As Latest Scam, Silver Remedy Firm Shut Down

Executive Summary

FTC warns 20 firms selling products or services promising to prevent or treat COVID-19, including three clinics saying peptides help boost the effectiveness of a vaccine. NJ business promoting collodial silver to prevent or treat novel coronavirus infection shut down in a DoJ complaint after failing to comply with regulatory agencies' warning.

You may also be interested in...



FDA Warns Against Using Compounded Remdesivir Due To Quality Concerns

Although compounding of certain shortage drugs is allowed during the public health emergency, remdesivir is off limits due to its complexity. Providers should only use the FDA-approved version of the drug, Gilead’s Veklury, the agency says.

US Agencies Warn Company Claiming Electromagnetic Nanoparticles ‘Eradicate’ COVID-19 Virus

Dallas-based Indigenous Products, which suggested online that its nebulizer-delivered electromagnetic silver nanoparticles could “eradicate” the novel coronavirus, is among the latest recipients of warning letters from the US FDA and/or FTC to firms making COVID-19 claims.

US COVID-19 Fraud: OTC Injectable Peptides Promoted As Treatment

Paradigm RE advised to take immediate action to correct violations for suggesting its injectable peptides could reduce acute lung injury in patients with COVID-19.

Related Content

Topics

UsernamePublicRestriction

Register

RS150695

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel